










ETUARY®

















IND (Investigative Drug Application) approved (May 2024)

F230

Indication: Pulmonary arterial hypertension(PAH)
Licensed from Eisai Co., Ltd.



IND application submitted (July 2024)

CG009301 (

5. Second Half of FY2024 Topics

Notable events in the 2nd half of 2024

1. Receive results of Phase 3 clinical trial of F351
2. Cullgen's

6. GNI G H Va



Group structure

100





F351 Phase 2 trial top-line data overview (2/3)

Efficacy results: additional analyses for patients with Ishak score = 6 (cirrhosis stage)

Efficacy analyses	Placebo	F351 (all groups)



